Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.

about

Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q50049497

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Recommendations on managing le ...... tastatic renal cell carcinoma.

@en

Recommendations on managing le ...... tastatic renal cell carcinoma.

@nl

type

Item

label

Recommendations on managing le ...... tastatic renal cell carcinoma.

@en

Recommendations on managing le ...... tastatic renal cell carcinoma.

@nl

prefLabel

Recommendations on managing le ...... tastatic renal cell carcinoma.

@en

Recommendations on managing le ...... tastatic renal cell carcinoma.

@nl

P1476

Recommendations on managing le ...... tastatic renal cell carcinoma.

@en

P2093

E Grande

http://www.w3.org/2001/XMLSchema#string

G Argenziano

http://www.w3.org/2001/XMLSchema#string

H Glen

http://www.w3.org/2001/XMLSchema#string

J L Zamorano

http://www.w3.org/2001/XMLSchema#string

J Larkin

http://www.w3.org/2001/XMLSchema#string

K Edmonds

http://www.w3.org/2001/XMLSchema#string

M J Lamas

http://www.w3.org/2001/XMLSchema#string

M Staehler

http://www.w3.org/2001/XMLSchema#string

P Ruszniewski

http://www.w3.org/2001/XMLSchema#string

S Sarker

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Angiogenesis therapy for the treatment of erectile dysfunction.

Drug-induced prolongation of the QT interval.

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

P304

1413-1426

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14740338.2017.1380624

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Javier Aller

P577

2017-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28920492

http://www.w3.org/2001/XMLSchema#string